Simple pill may prevent painful urinary blockage after prostate biopsy
NCT ID NCT07276919
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether taking tamsulosin, a drug often used for enlarged prostate, can prevent difficulty urinating after a prostate biopsy. About 1,844 men will either take the drug for a few days around the biopsy or receive no preventive medication. The goal is to see if the drug lowers the chance of needing a catheter and improves overall urinary symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tamsulosin Hydrochloride (0.2 mg sustained-release capsules)
What this could lead to
If it works, this could provide a simple, short-term medication to prevent painful urinary retention and improve urination after a prostate biopsy.
What could go wrong
This is a Phase 4 trial, but it has not yet started recruiting. The benefit may be small, and some men may still experience urinary problems despite treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE URINARY RETENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital, Urology Department
Beijing, Outside U.S./Canada, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••